Ascletis Pharma Inc.
ASCLF - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$748.65M
Close$
$0.22
69.7% downside
Current Fair Value
69.7% downsideOvervalued by 69.7% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $748.65 Million |
|---|---|
| Enterprise Value | $159.03 Million |
| Earnings per Share | $-0.36 |
| Beta | 0.43 |
| Outstanding Shares | 1,039,794,415 |
Return
| Return on Equity | -37.24% |
|---|---|
| Return on Assets | -34.49% |
| Return on Invested Capital | -47.60% |
Valuation & Multiples
| P/E Ratio | -7.03 |
|---|---|
| PEG | -2.67 |
| Price to Sales | - |
| Price to Book Ratio | 0.36 |
| Enterprise Value to Revenue | 48.26 |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 31, 2026
EPS Estimate
$-0.03
Consensus analyst estimateRevenue Estimate
$4.07 M
Consensus analyst estimateNext Earnings Call
Expected Date
March 30, 2027
EPS Estimate
$-0.06
Consensus analyst estimateRevenue Estimate
$6.22 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About Ascletis Pharma Inc.
202 employees
CEO: Jinzi J. Wu
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEV...